GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

dapirolizumab pegol   Click here for help

GtoPdb Ligand ID: 11123

Synonyms: CDP-7657 | CDP7657 | DZP
Immunopharmacology Ligand
Compound class: Antibody
Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.
No information available.
Summary of Clinical Use Click here for help
Dapirolizumab pegol (CDP7657) has progressed to Phase 3 evaluation for SLE.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04294667 A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus Phase 3 Interventional UCB Pharma
NCT01093911 Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) Phase 1 Interventional UCB Pharma 2